Does Anastrozole Cause Atrial Fibrillation?
Yes, anastrozole is associated with an increased risk of atrial fibrillation (AF), particularly in the first 5 years of treatment, though the absolute risk remains relatively low.
Evidence from Clinical Trials and Guidelines
The available evidence demonstrates a modest but real association between anastrozole and AF risk:
Comparative Risk: Anastrozole vs. Tamoxifen
The most recent and highest-quality evidence shows anastrozole increases AF risk compared to tamoxifen in the short-to-medium term 1. In a large retrospective cohort study (2025) analyzing over 220,000 patients:
- At 1 year: AF incidence was 0.5% with AIs vs. 0.4% with tamoxifen (RR: 1.36, p=0.001)
- At 5 years: AF incidence was 1.2% with AIs vs. 1.1% with tamoxifen (RR: 1.13, p=0.035)
- At 10 years: The difference equalized (1.6% vs. 1.5%, RR: 1.05, p=0.295)
A 2024 Hong Kong study of 5,707 breast cancer patients confirmed this finding, showing AI users had more than double the risk of new-onset AF compared to tamoxifen users (adjusted HR: 2.75, p=0.01) 2.
Mechanism and Context
The increased AF risk with anastrozole is biologically plausible due to estrogen depletion. Aromatase inhibitors profoundly suppress estrogen levels (reducing estradiol by ~80% within 14 days) 3, and this hormonal change may affect cardiac electrophysiology and atrial remodeling.
Notably, the NCCN guidelines acknowledge different cardiovascular toxicity profiles between anastrozole and tamoxifen. While anastrozole is associated with more strokes 4, tamoxifen carries higher risks of venous thromboembolism. The FDA label for anastrozole warns about heart disease risks, particularly in women with pre-existing ischemic heart disease 3.
Clinical Implications and Risk Stratification
Age-Dependent Risk
Younger breast cancer survivors face disproportionately higher AF risk 5:
- Women <40 years: 2.79-fold increased AF risk
- Women >65 years: No significant increase observed
This age gradient is critical for risk assessment and monitoring strategies.
Additional Risk Factors
The 2016 ESC position paper notes that aromatase inhibitors are associated with higher rates of arterial thrombotic events compared to tamoxifen 6. When combined with anthracycline chemotherapy, AF risk increases further (HR: 1.57 overall; HR: 1.94 in women ≤50 years) 5.
Practical Management Approach
Pre-Treatment Assessment
Before initiating anastrozole, evaluate:
- Baseline cardiovascular risk factors (hypertension, diabetes, obesity, sleep apnea)
- Pre-existing cardiac disease, especially ischemic heart disease
- Age (younger patients warrant closer monitoring)
- Concurrent cardiotoxic therapies (anthracyclines, trastuzumab)
Monitoring Strategy
- Years 1-5: Heightened surveillance for AF symptoms (palpitations, dyspnea, fatigue, dizziness)
- Younger patients (<50 years): Consider more frequent cardiovascular assessments
- Patients with anthracycline exposure: Enhanced monitoring throughout treatment
When to Consider Tamoxifen Instead
The NCCN guidelines specifically recommend considering aromatase inhibitors for postmenopausal women "especially those with concerns of embolism" 4. This implicitly acknowledges the differential cardiovascular risk profiles. Consider tamoxifen over anastrozole in postmenopausal women with:
- Pre-existing AF or significant AF risk factors
- History of stroke or TIA
- Multiple cardiovascular comorbidities
- Age <50 years with additional cardiac risk factors
Important Caveats
The absolute risk of AF remains relatively low (1-2% over 5 years), and the cancer mortality benefit of anastrozole generally outweighs the AF risk in most postmenopausal women with hormone receptor-positive breast cancer. The IBIS-II and NSABP B-35 trials showed superior breast cancer-free intervals with anastrozole compared to tamoxifen 4.
Do not discontinue anastrozole solely due to AF concerns without oncology consultation, as this could compromise cancer outcomes. Instead, optimize AF management (rate/rhythm control, anticoagulation if indicated) while continuing cancer therapy.
The key is individualized risk-benefit assessment: younger patients, those with pre-existing cardiac disease, and those receiving concurrent cardiotoxic therapies warrant closer cardiovascular monitoring and potentially alternative endocrine therapy selection 1, 2.